11.12.17

RESOLUTIONS AT THE EXTRAORDINARY GENERAL MEETING OF NUEVOLUTION AB (PUBL)

08.12.17

THE DANISH EASTERN HIGH COURT REVOKES THE MARITIME AND COMMERCIAL HIGH COURT’S DECISION OF 22 FEBRUARY 2016 IN FAVOUR OF NUEVOLUTION’S REQUEST

27.11.17

NUEVOLUTION TO PRESENT NEW DATA ON ITS BET BD1 PROGRAM SUPPORTING EFFECT IN PSORIASIS/ATOPIC DERMATITIS

20.11.17

NOTICE OF EXTRAORDINARY GENERAL MEETING OF NUEVOLUTION AB (PUBL)

07.11.17

NUEVOLUTION AB (PUBL) ANNOUNCES ITS REPORT FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2017

03.11.17

NUEVOLUTION APPOINTS JOHNNY STILOU AS DIRECTOR OF INVESTOR RELATIONS AND CORPORATE COMMUNICATION

01.11.17

NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE RELEASE AND WEBCAST OF THE THREE-MONTH REPORT FOR JULY-SEPTEMBER 2017

30.10.17

FREDRIK ARP IS PROPOSED AS BOARD MEMBER IN NUEVOLUTION AB (PUBL)

27.10.17

NUEVOLUTION TO PRESENT NEW DATA ON ITS BET BD1 PROGRAM SUPPORTING THE UNDERSTANDING OF THE BIOLOGICAL MODE-OF-ACTION

12.10.17

RESOLUTIONS AT THE ANNUAL GENERAL MEETING OF NUEVOLUTION AB (PUBL)

12.10.17

PRESENTATION FOR NUEVOLUTION’S ANNUAL GENERAL MEETING AND VIDEO MATERIAL BASED ON THE ANNUAL REPORT 2016/17 NOW AVAILABLE

18.09.17

NUEVOLUTION AB (PUBL) ANNUAL REPORT 2016/17 NOW AVAILABLE

18.09.17

NUEVOLUTION AB (PUBL) INTENDS TO MOVE THE LISTING OF ITS SHARES TO NASDAQ STOCKHOLM’S MAIN MARKET DURING THE FISCAL YEAR 2017/18

12.09.17

NOTICE OF ANNUAL GENERAL MEETING OF NUEVOLUTION AB (PUBL)

11.09.17

NUEVOLUTION TO PRESENT AT THREE INVESTOR CONFERENCES IN SEPTEMBER 2017

06.09.17

NUEVOLUTION AB (PUBL) ANNOUNCES ITS RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2016/17

30.08.17

CORRECTION OF: NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE FOURTH QUARTER RELEASE AND WEBCAST

30.08.17

NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE FOURTH QUARTER RELEASE AND WEBCAST

19.06.17

NUEVOLUTION PRESENTS ADDITIONAL POSITIVE ANIMAL RESULTS IN LUPUS FROM ITS BET SELECTIVE PROGRAM

12.06.17

NUEVOLUTION TO PRESENT AT ANGLO-NORDIC MEDICINAL CHEMISTRY SYMPOSIUM

17.05.17

NUEVOLUTION AB (PUBL) ANNOUNCES ITS RESULTS FOR THE THIRD QUARTER 2016/17

10.05.17

NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE THIRD QUARTER RELEASE AND WEBCAST

20.03.17

BIOEUROPE SPRING 2017 PRESENTATION OF PROGRESS IN THREE PIPELINE PROGRAMS

06.03.17

NUEVOLUTION ANNOUNCES FURTHER TECHNOLOGY ACCESS FEE PAYMENT FROM ITS DRUG DISCOVERY COLLABORATION WITH JANSSEN

14.02.17

NUEVOLUTION TECHNOLOGY PROGRESS: NUEVOLUTION SCALES ITS COMPOUND COLLECTION TO 40 TRILLION USING ITS CHEMETICS™ DRUG DISCOVERY PLATFORM

08.02.17

NUEVOLUTION AB (PUBL) ANNOUNCES ITS RESULTS FOR THE SECOND QUARTER 2016/17

02.02.17

NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE SECOND QUARTER RELEASE AND WEBCAST

23.01.17

NUEVOLUTION ANNOUNCES THE PUBLICATION OF A SCIENTIFIC ARTICLE IN COLLABORATION WITH NOBEL LAUREATE DR. ROBERT J. LEFKOWITZ

12.12.16

CONFERENCE CALL TO DISCUSS THE STRATEGIC COLLABORATION WITH ALMIRALL

12.12.16

ALMIRALL AND NUEVOLUTION ENTER INTO A STRATEGIC COLLABORATION TO DEVELOP RORγt INHIBITORS FOR TREATMENT OF DERMATOLOGY DISEASES AND PSORIATIC ARTHRITIS

02.12.16

NUEVOLUTION RECEIVES RESEARCH GRANT AND ENTERS COLLABORATION ON DEVELOPMENT OF NEW TAILORED CANCER THERAPEUTICS

17.11.16

NUEVOLUTION AB (PUBL) ANNOUNCES ITS RESULTS FOR THE FIRST QUARTER 2016/17

11.11.16

NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE FIRST QUARTER RELEASE AND WEBCAST

08.11.16

NUEVOLUTION TO PRESENT AT UPCOMING INVESTOR CONFERENCES

04.11.16

NUEVOLUTION APPOINTS REDEYE AS CERTIFIED ADVISER

05.10.16

ANNUAL GENERAL MEETING OF NUEVOLUTION AB (PUBL)

04.10.16

CONFERENCE CALL TO DISCUSS THE STRATEGIC COLLABORATION WITH AMGEN

04.10.16

NUEVOLUTION ANNOUNCES STRATEGIC COLLABORATION WITH AMGEN IN ONCOLOGY AND NEUROSCIENCE

22.09.16

ORAL PRESENTATION OF PRECLINICAL AND PRELIMINARY TOXICOLOGY DATA ON ITS BET BD1 PROGRAM AT DISCOVERY ON TARGET 2016

16.09.16

PRESENTATION OF PRECLINICAL DATA ON ITS BET BD1 PROGRAM AT DISCOVERY ON TARGET 2016

15.09.16

NUEVOLUTION AB (PUBL) ANNUAL REPORT 2015/16 NOW AVAILABLE

06.09.16

Q4 2015/16 QUARTERLY REPORT WEBCAST AND PRESENTATION

06.09.16

NUEVOLUTION AB (PUBL) ANNOUNCES ITS RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2015/16

05.09.16

NOTICE OF ANNUAL GENERAL MEETING OF NUEVOLUTION AB (PUBL)

29.08.16

NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE FOURTH QUARTER RELEASE AND WEBCAST

25.08.16

PRESENTATION OF DISCOVERY DATA FROM THE GRP78 INHIBITOR PROGRAM AT EFMC-ISMC 2016

23.08.16

NUEVOLUTION TO PRESENT AT THE 18TH ANNUAL RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE

16.08.16

PRESENTATION OF PRECLINICAL DATA FROM RORƴt INVERSE AGONIST PROGRAM AT ICI 2016

01.07.16

EXTRAORDINARY GENERAL MEETING OF NUEVOLUTION AB (PUBL)

01.06.16

NOTICE OF EXTRAORDINARY GENERAL MEETING OF NUEVOLUTION AB (PUBL)

20.05.16

REPLAY OF TWO INVESTOR PRESENTATIONS AVAILABLE

11.05.16

Q3 2015/16 QUARTERLY REPORT WEBCAST AND PRESENTATION

10.05.16

NUEVOLUTION AB (PUBL) ANNOUNCES ITS QUARTERLY RESULTS FOR THE THIRD QUARTER 2015/16

06.05.16

NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE THIRD QUARTER RELEASE AND WEBCAST

20.04.16

NUEVOLUTION ANNOUNCES FURTHER TECHNOLOGY ACCESS FEE PAYMENT FROM ITS DRUG DISCOVERY COLLABORATION WITH JOHNSON & JOHNSON INNOVATION

04.03.16

THE EUROPEAN PATENT OFFICE ISSUES FOUR PATENTS TO NUEVOLUTION AB (PUBL)

22.02.16

THE DANISH SØ- OG HANDELSRETTEN ISSUES A DECISION ON SEPARATE QUESTIONS IN THE CASE BETWEEN NUEVOLUTION AND HENRIK PEDERSEN/CHEMGENE HOLDING APS

22.02.16

NUEVOLUTION AB (PUBL) ANNOUNCES MILESTONE PAYMENT FROM BIG PHARMA COLLABORATION

04.02.16

QUARTERLY REPORT (Q2 2015/16) WEBCAST

02.02.16

CHANGE IN NUEVOLUTION’S BOARD OF DIRECTORS

26.01.16

NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE SECOND QUARTER RELEASE AND WEBCAST

18.11.15

NUEVOLUTION A/S APPOINTS PROFESSOR MARK C. GENOVESE, MD AS ADVISOR TO SUPPORT THE COMPANY’S PRE-CLINICAL AND CLINICAL EFFORTS IN INFLAMMATORY DISEASES

19.10.15

NUEVOLUTION ANNOUNCES DRUG DISCOVERY COLLABORATION WITH JOHNSON & JOHNSON INNOVATION

28.09.15

NUEVOLUTION A/S APPOINTS DR. KEITH NOLOP AS ADVISOR FOR PRE-CLINICAL AND CLINICAL DRUG DEVELOPMENT

21.09.15

DR. JEANETTE WOOD HAS JOINED NUEVOLUTION AS DIRECTOR AND SENIOR SCIENTIFIC ADVISOR TO THE BOARD OF DIRECTORS

16.09.15

NUEVOLUTION APPOINTS HENRIK SIMONSEN, FORMER DIRECTOR OF LIFE SCIENCE CORPORATE FINANCE AT SEB, AS ITS CHIEF FINANCIAL OFFICER

09.07.14

PROFESSOR PAUL WORKMAN JOINS NUEVOLUTION AS SCIENTIFIC ADVISOR

26.06.14

SERIAL ENTREPRENEUR DR. PETER HIRTH JOINS NUEVOLUTION AS CORPORATE ADVISOR

21.05.14

DR. BRIAN ZAMBROWICZ, PH.D HAS JOINED NUEVOLUTION AS DIRECTOR AND SENIOR SCIENTIFIC ADVISOR TO THE BOARD OF DIRECTORS

20.02.14

NUEVOLUTION ANNOUNCES LICENSE AGREEMENT WITH MERCK

22.01.14

NUEVOLUTION ENTER DRUG DISCOVERY COLLABORATION WITH THE INSTITUTE OF CANCER RESEARCH (ICR) AND CANCER RESEARCH TECHNOLOGY (CRT)

10.01.14

NUEVOLUTION ANNOUNCES TECHNOLOGY LICENSING AGREEMENT

19.12.13

NUEVOLUTION APPOINTS TON BERKIEN AS CHIEF BUSINESS OFFICER

04.11.13

CANCER RESEARCH TECHNOLOGY AND NUEVOLUTION SIGN MULTI-TARGET DEAL TO SEEK POTENTIAL CANCER DRUGS

19.08.13

PROFESSOR DR. JUTTA HEIM HAS JOINED NUEVOLUTION AS DIRECTOR AND SENIOR SCIENTIFIC ADVISOR TO THE BOARD OF DIRECTORS

12.08.13

HOWARD HUGHES MEDICAL INSTITUTE, LEXICON PHARMACEUTICALS, NUEVOLUTION AND LEADING RESEARCH UNIVERSITY FORM SCIENTIFIC COLLABORATION

13.03.13

NUEVOLUTION ANNOUNCES FORMATION OF STRONG SCIENTIFIC ADVISORY PANEL

19.06.12

NUEVOLUTION A/S RAISES €11 MILLION IN NEW FINANCING ROUND

09.05.12

NUEVOLUTION ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM BOEHRINGER INGELHEIM

19.09.11

NUEVOLUTION ANNOUNCES COLLABORATION IN DRUG DISCOVERY WITH BOEHRINGER INGELHEIM

06.10.10

NUEVOLUTION ENTERS LEAD DISCOVERY COLLABORATION IN THE FIELD OF EPIGENETIC DISORDERS